A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with ß-thalassemia major

被引:8
|
作者
Elalfy, Mohsen S. [1 ]
Massoud, Walid [2 ]
Elsherif, Nayera H. [1 ]
Labib, Jonair H. [1 ]
Elalfy, Omar M. [1 ]
Elaasar, Safaa [3 ]
von Mackensen, Sylvia [4 ]
机构
[1] Ain Shams Univ, Pediat Thalassemia Ctr, Cairo, Egypt
[2] Amer Univ Cairo, Educ Testing & Assessment Div, Cairo, Egypt
[3] Ain Shams Univ, Dept Psychol, Fac Women, Cairo, Egypt
[4] Univ Med Ctr Hamburg Eppendorf UKE, Inst & Policlin Med Psychol Hamburg, Hamburg, Germany
关键词
adherence; ICT-Sat; iron chelators; patient-rated outcome; questionnaire; Thalassemia; QUALITY-OF-LIFE; BETA-THALASSEMIA; CARDIAC IRON; DESFERRIOXAMINE TREATMENT; OVERLOADED PATIENTS; DEFERASIROX; DEFERIPRONE; TRANSFUSION; DEFEROXAMINE; EFFICACY;
D O I
10.1002/pbc.23413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background High satisfaction with iron chelation is a major determinant for adherence to ICT in beta-thalassaemia major (beta-TM) patients. In this study, a new tool to assess different domains of satisfaction for available forms of ICT was developed and validated. The impact of patients' satisfaction with ICT has been tested. Methods. Items were generated via focus groups and a preliminary version with 24 items (ICT-Sat) with an additional item for treatment preference and a knowledge questionnaire (KQ) was developed. 170 beta-TM patients from three Thalassaemia centers in Egypt, aged 2-32 years received three questionnaires to fill in; the new ICT-Sat, a KQ, and a previously validated tool for satisfaction with ICT (SICT) and retested 4-6 weeks later to ensure re-test reliability. Type of chelation, drug related adverse events, compliance with ICT, and serum ferritin level (SF) during the year prior to the study as well as available cardiac T2*data were recorded. Results. One hundred and fifty two beta-TM patients completed all questionnaires; median age was 12 years. The final 15 remaining ICT-Sat items, yielding to four domain scores, explained 70.6% of the total variance. The "perceived effectiveness" and "fear and worries" domains of the ICT-Sat correlated significantly with the domains "perceived effectiveness" and "acceptance" of the SICT. Patients treated with oral ICT were more satisfied with perceived effectiveness, and their side effects. Conclusions. A new clinically based ICT-Sat tool was developed and revealed good psychometric characteristics. Adherence to ICT was better correlated with "perceived effectiveness" and SF level. Pediatr Blood Cancer 2012; 58: 910-915. (C) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:910 / 915
页数:6
相关论文
共 50 条
  • [41] Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in β-thalassemia major patients
    Wang, Chung-Hsing
    Wu, Kang-Hsi
    Tsai, Fuu-Jen
    Peng, Ching-Tien
    Tsai, Chang-Hai
    HEMOGLOBIN, 2006, 30 (02) : 257 - 262
  • [42] Long Term Efficacy Of Iron Chelation Therapy With Deferasirox On Endocrine Function In Thalassemia Major
    Casale, Maddalena
    Citarella, Serena
    Filosa, Aldo
    De Michele, Elisa
    Pugliese, Umberto
    Francesco, Palmieri
    Ragozzino, Alfonso
    Giovanni, Amendola
    Tartaglione, Immacolata
    Della Rocca, Milena
    Nobili, Bruno
    Silverio, Perrotta
    BLOOD, 2013, 122 (21)
  • [43] Hypoparathyroidism in children with beta-thalassemia major and its relation to iron chelation therapy
    El-Din, Lerine Bahy
    Ebeid, Fatma S. E.
    Toaima, Nadin N.
    Ibrahim, Walaa W.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2018, 43 (02): : 63 - 68
  • [44] Impact of Iron Chelation Therapy Adherence on Prediabetes Development in Young Adult β-Thalassemia Major Patients: A Comparative Analysis
    De Sanctis, Vincenzo
    Soliman, Ashraf
    Daar, Shahina
    Campisi, Saveria
    Tzoulis, Ploutarchos
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 423 - 424
  • [45] Long-term effects of combined chelation therapy in thalassemia major patients with iron-induced cardiomyopathy
    Pepe, A.
    Grady, R.
    Vacquer, S.
    Carta, P.
    Sau, F.
    Bina, P.
    Cianciulli, P.
    Maggio, A.
    Lombardi, M.
    Lai, M. E.
    EUROPEAN HEART JOURNAL, 2007, 28 : 51 - 51
  • [46] Iron Chelation Therapy in Transfusion Dependent Patients with Thalassemia and Minimal Liver Iron Load
    Kattamis, Antonios
    Stokidis, Konstantinos
    Petropoulou, Tbeoni
    Kyriacopoulou, Dimitra
    Delaporta, Polyxeni
    Papassptiriou, Ioannis
    Ladis, Vassilis
    BLOOD, 2010, 116 (21) : 1733 - 1733
  • [47] Development and scoring of the satisfaction with iron chelation therapy instrument for patients with iron overload
    Rofail, D.
    Viala, M.
    Abetz, L.
    Gait, C.
    VALUE IN HEALTH, 2006, 9 (06) : A251 - A251
  • [48] A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major
    Fernandes, Juliano L.
    Loggetto, Sandra R.
    Verissimo, Monica P. A.
    Fertrin, Kleber Y.
    Baldanzi, Giorgio R.
    Fioravante, Luciana A. B.
    Tan, Doralice M.
    Higa, Tatiana
    Mashima, Denise A.
    Piga, Antonio
    Coelho, Otavio R.
    Costa, Fernando F.
    Saad, Sara T.
    BLOOD, 2016, 128 (12) : 1555 - 1561
  • [49] Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment
    Danjou, F.
    Origa, R.
    Anni, F.
    Saba, L.
    Cossa, S.
    Podda, G.
    Galanello, R.
    BLOOD CELLS MOLECULES AND DISEASES, 2013, 51 (03) : 142 - 145
  • [50] Can Oral Iron Chelation Therapies Reduce Endocrine Complications in β-Thalassemia Major Patients?
    Rostami, Parastoo
    Mohsenipour, Reyhaneh
    Khoshkbarforoshan, Mina
    Sayarifard, Fatemeh
    Setoudeh, Arya
    Safari, Alieh
    Kompani, Farzad
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 481 - 481